Yazan Madanat, MD, UT Southwestern Medical Center, Dallas, TX, outlines his plan to treat higher-risk myelodysplastic syndromes (MDS) in 2027. Dr Madanat highlights why recent doublet trials have failed, the emerging role of oral hypomethylating agents, novel BCL-2 inhibitors, intensive chemotherapy, and IDH1 inhibition, and a treatment algorithm guided by genetic subtype, blast percentage, and transplant candidacy. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.